<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262794</url>
  </required_header>
  <id_info>
    <org_study_id>RA0074</org_study_id>
    <secondary_id>2010-022543-38</secondary_id>
    <nct_id>NCT01262794</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo Controlled, Single-center, Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of CDP6038 Administered Subcutaneously to Healthy Japanese Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of CDP6038 following single dose subcutaneous (sc)
      administration of CDP6038 to Japanese subjects.

      To evaluate the Pharmacokinetics of CDP6038 following single dose sc administration of
      CDP6038 to Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable level (AUC0-t)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration versus time curve extrapolated to infinity (AUC)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (TÂ½)</measure>
    <time_frame>Multiple sampling from 0 to 113 days following single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK/PD relationship between systemic CDP6038 exposure and suppression of selected acute phase markers (such as C-reactive protein), following single subcutaneous doses of CDP6038 in Japanese subjects</measure>
    <time_frame>Multiple sampling from 0 to 15 weeks following single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of single subcutaneous doses of CDP6038 in Japanese subjects</measure>
    <time_frame>Multiple sampling from 0 to 15 weeks following single dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CDP6038 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CDP6038 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CDP6038 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CDP6038 6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDP6038</intervention_name>
    <description>100 mg/mL solution for injection, single dose</description>
    <arm_group_label>CDP6038 0.3 mg/kg</arm_group_label>
    <arm_group_label>CDP6038 1 mg/kg</arm_group_label>
    <arm_group_label>CDP6038 3 mg/kg</arm_group_label>
    <arm_group_label>CDP6038 6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection Single-dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese volunteers

        Exclusion Criteria:

          -  Subject has participated in any other clinical drug study (including a biologic
             product or a medical device) within 5 PK half-lives or 3 months (whichever is longer)
             prior to Screening, or the subject is currently participating in another clinical
             study.

          -  Subject is not healthy (eg, taking any drug treatments, any psychological or emotional
             problems, a drug/alcohol abuse or a having a history of drug/alcohol abuse, having
             abnormal safety parameters)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>September 26, 2011</last_update_submitted>
  <last_update_submitted_qc>September 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Japanese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

